Open AccessTrial by CCN2: a standardized test for fibroproliferative disease?
Author(s) -
Leask Andrew
Publication year - 2009
Publication title -
journal of cell communication and signaling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 44
eISSN - 1873-961X
pISSN - 1873-9601
DOI - 10.1007/s12079-009-0041-y
Subject(s) - ctgf , vascular endothelial growth factor , biomarker , medicine , growth factor , clinical trial , connective tissue , drug development , vegf receptors , diabetic retinopathy , bioinformatics , pathology , drug , biology , pharmacology , diabetes mellitus , endocrinology , biochemistry , receptor
A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relative levels of vascular endothelial growth factor (VEGF) and CCN2 (connective tissue growth factor [CTGF]) were examined in proliferative diabetic retinopathy (PDR). This paper is the subject of this commentary.